Print

MiMedx Signs Agreement with Systagenix for Global Distribution of EpiFix(R)  
3/20/2012 9:26:25 AM

KENNESAW, Ga., March 19, 2012 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today the signing of a global distribution agreement with Systagenix, whereby Systagenix will co-market EpiFix®. The MiMedx branded and proprietary biologic implant specifically processed from amniotic tissue, EpiFix® offers a wide variety of wound healing and wound care options.

Based in Gatwick, United Kingdom, Systagenix will commence its launch of EpiFix® during March 2012. As part of its global distribution agreement with MiMedx, Systagenix will initially conduct the first phase of its global launch of EpiFix® throughout the United States, with launches in other countries to follow pending appropriate regulatory approvals. MiMedx will also continue to sell EpiFix® through its existing distributor channels.

EpiFix® is another of the MiMedx tissue offerings uniquely processed through the Company's proprietary Purion(SM) Process to optimize wound care and ease of use. EpiFix® is an allograft from amniotic tissue which has been shown to promote the healing of soft tissues. The Purion(SM) Process retains the amniotic growth factors inherent in and unique to placental tissue which promotes cellular ingrowth and enhanced healing.

EpiFix® has unique and differentiating characteristics such as its 5-year shelf life and stability at room temperature, its ease of handling and manipulation by physicians, its disinfection process that protects any compromise of the amniotic membrane delicate structure and its clinical history and testing results confirming that EpiFix® retains several growth factors associated with promoting cell proliferation.

Parker H. "Pete" Petit, Chairman and CEO, said, "We are very pleased with this opportunity to partner with Systagenix. The combined efforts of the Systagenix sales and marketing team with our existing sales, marketing and distribution channels will allow us to more effectively reach the advanced wound care therapies segment of the market."

About Systagenix

Established in 2008, following the acquisition of Johnson & Johnson's advanced wound care business, Systagenix supplies advanced wound dressings into over 100 countries worldwide. Information on Systagenix wound care can be found at www.systagenix.com.

About MiMedx

MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies, processed from the human amniotic membrane, utilize our proprietary Purion(SM) Process that was developed by our wholly-owned subsidiary, Surgical Biologics, to produce a safe, effective and minimally manipulated implant for homologous use. Surgical Biologics is the leading supplier of amniotic tissue, having supplied over 70,000 implants to date to distributors and OEMs for application in the Ophthalmic, Orthopedics, Spine, Wound Care and Dental sectors of healthcare.

Safe Harbor Statement

This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes. Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to the increased usage of EpiFix® within the advanced wound care therapies market segment as a result of the agreement with Systagenix and the launch of EpiFix® in countries beyond the U.S. following regulatory approval. These statements are based on current information and belief, and are not guarantees of future performance. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that the increased usage of EpiFix® in the advanced wound care therapies market segment as a result of the agreement with Systagenix may not materialize as anticipated, that the launch of EpiFix® in countries beyond the U.S. may not materialize or may be delayed due to regulatory approval, and the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2010, and its most recent Form 10-Q. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company's disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.

SOURCE MiMedx, Inc.


//-->